Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.

Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2020 Mar 10. doi: 10.1002/cncr.32785. [Epub ahead of print] No abstract available.

PMID:
32154908
2.

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.

Lu C, Brown LC, Antonarakis ES, Armstrong AJ, Luo J.

Prostate Cancer Prostatic Dis. 2020 Mar 5. doi: 10.1038/s41391-020-0217-3. [Epub ahead of print] Review.

PMID:
32139878
3.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS.

Prostate Cancer Prostatic Dis. 2020 Feb 28. doi: 10.1038/s41391-020-0213-7. [Epub ahead of print]

PMID:
32111923
4.

A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).

Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler H, Posadas EM, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH.

Clin Cancer Res. 2020 Feb 27. pii: clincanres.3873.2019. doi: 10.1158/1078-0432.CCR-19-3873. [Epub ahead of print]

PMID:
32108029
5.

Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Brown LC, Lu C, Antonarakis ES, Luo J, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2020 Feb 24. doi: 10.1038/s41391-020-0215-5. [Epub ahead of print] Review.

PMID:
32094489
6.

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ.

Eur Urol Oncol. 2020 Feb 13. pii: S2588-9311(20)30020-1. doi: 10.1016/j.euo.2020.01.005. [Epub ahead of print]

PMID:
32063492
7.

Can gut microbiota of men who have sex with men influence HIV transmission?

Coleman SL, Neff CP, Li SX, Armstrong AJS, Schneider JM, Sen S, Fennimore B, Campbell TB, Lozupone CA, Palmer BE.

Gut Microbes. 2020 Feb 10:1-10. doi: 10.1080/19490976.2019.1700756. [Epub ahead of print]

PMID:
32036739
8.

Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.

Kinsey EN, Zhang T, Armstrong AJ.

Cancer J. 2020 Jan/Feb;26(1):64-75. doi: 10.1097/PPO.0000000000000418.

PMID:
31977388
9.

The geographic distribution of reef and oceanic manta rays (Mobula alfredi and Mobula birostris) in Australian coastal waters.

Armstrong AJ, Armstrong AO, Bennett MB, McGregor F, Abrantes KG, Barnett A, Richardson AJ, Townsend KA, Dudgeon CL.

J Fish Biol. 2020 Mar;96(3):835-840. doi: 10.1111/jfb.14256. Epub 2020 Jan 28.

PMID:
31925780
10.

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.

Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM.

JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4636. [Epub ahead of print]

11.

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.

Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H.

J Clin Oncol. 2019 Dec 12:JCO1902768. doi: 10.1200/JCO.19.02768. [Epub ahead of print]

PMID:
31829902
12.

Rapid wound healing in a reef manta ray masks the extent of vessel strike.

McGregor F, Richardson AJ, Armstrong AJ, Armstrong AO, Dudgeon CL.

PLoS One. 2019 Dec 11;14(12):e0225681. doi: 10.1371/journal.pone.0225681. eCollection 2019.

13.

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.

Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J.

Sci Transl Med. 2019 Dec 4;11(521). pii: eaax0428. doi: 10.1126/scitranslmed.aax0428.

PMID:
31801883
14.

Has Mismatch Repair-Deficient Cancer Met Its MATCH?

Brown LC, Armstrong AJ.

J Clin Oncol. 2020 Jan 20;38(3):183-187. doi: 10.1200/JCO.19.02860. Epub 2019 Dec 3. No abstract available.

PMID:
31794325
15.

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.

Gupta S, Hovelson DH, Kemeny G, Halabi S, Foo WC, Anand M, Somarelli JA, Tomlins SA, Antonarakis ES, Luo J, Dittamore RV, George DJ, Rothwell C, Nanus DM, Armstrong AJ, Gregory SG.

Genes Chromosomes Cancer. 2020 Apr;59(4):225-239. doi: 10.1002/gcc.22824. Epub 2019 Nov 28.

PMID:
31705765
16.

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, Wood SY, Spritzer C, Madden JF, Armstrong AJ.

Urol Oncol. 2020 Mar;38(3):79.e15-79.e22. doi: 10.1016/j.urolonc.2019.08.015. Epub 2019 Sep 12.

PMID:
31522863
17.

Molecular determinants for enzalutamide-induced transcription in prostate cancer.

Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q.

Nucleic Acids Res. 2019 Nov 4;47(19):10104-10114. doi: 10.1093/nar/gkz790.

18.

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ.

Prostate. 2019 Nov;79(15):1752-1761. doi: 10.1002/pros.23899. Epub 2019 Sep 9.

PMID:
31497882
19.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.

20.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.

J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.

PMID:
31329516
21.

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.

Urol Oncol. 2019 Nov;37(11):813.e1-813.e9. doi: 10.1016/j.urolonc.2019.06.015. Epub 2019 Jul 19.

PMID:
31327751
22.

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.

Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM.

Eur Urol Oncol. 2019 Nov;2(6):677-684. doi: 10.1016/j.euo.2018.11.005. Epub 2018 Dec 3.

23.

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.

Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3.

24.

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Scher HI, Antonarakis ES, George DJ.

J Clin Oncol. 2019 Aug 20;37(24):2184-2186. doi: 10.1200/JCO.19.01230. Epub 2019 Jul 2. No abstract available.

PMID:
31265357
25.

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.

Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G.

Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29.

PMID:
31142515
26.

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, Gerber D, Anand M, Foo WC, Halabi S, Gregory SG, George DJ.

PLoS One. 2019 May 28;14(5):e0216934. doi: 10.1371/journal.pone.0216934. eCollection 2019.

27.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
28.

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ.

Prostate. 2019 Jul;79(10):1106-1116. doi: 10.1002/pros.23822. Epub 2019 May 2.

PMID:
31045266
29.

Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.

Mota JM, Armstrong AJ, Larson SM, Fox JJ, Morris MJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):522-530. doi: 10.1038/s41391-019-0151-4. Epub 2019 Apr 29. Review.

PMID:
31036925
30.

Development and characterization of 17 polymorphic microsatellite markers for the reef manta ray (Mobula alfredi).

Armstrong AJ, Dudgeon CL, Bustamante C, Bennett MB, Ovenden JR.

BMC Res Notes. 2019 Apr 22;12(1):233. doi: 10.1186/s13104-019-4270-8.

31.

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):588-592. doi: 10.1038/s41391-019-0144-3. Epub 2019 Apr 12.

32.

Gut microbiota from high-risk men who have sex with men drive immune activation in gnotobiotic mice and in vitro HIV infection.

Li SX, Sen S, Schneider JM, Xiong KN, Nusbacher NM, Moreno-Huizar N, Shaffer M, Armstrong AJS, Severs E, Kuhn K, Neff CP, McCarter M, Campbell T, Lozupone CA, Palmer BE.

PLoS Pathog. 2019 Apr 4;15(4):e1007611. doi: 10.1371/journal.ppat.1007611. eCollection 2019 Apr.

33.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.

PMID:
30865549
34.

E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.

Jolly MK, Ware KE, Xu S, Gilja S, Shetler S, Yang Y, Wang X, Austin RG, Runyambo D, Hish AJ, Bartholf DeWitt S, George JT, Kreulen RT, Boss MK, Lazarides AL, Kerr DL, Gerber DG, Sivaraj D, Armstrong AJ, Dewhirst MW, Eward WC, Levine H, Somarelli JA.

Mol Cancer Res. 2019 Jun;17(6):1391-1402. doi: 10.1158/1541-7786.MCR-18-0763. Epub 2019 Mar 12.

35.

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T.

Clin Genitourin Cancer. 2019 Jun;17(3):e513-e521. doi: 10.1016/j.clgc.2019.01.017. Epub 2019 Feb 5. Review.

PMID:
30858035
36.

Injuries involving the central tarsal bone in nonracing dogs: Short-term outcomes and prognostic factors.

Armstrong AJ, Bruce M, Adams R, Kulendra E, Pease T, Perry KL.

Vet Surg. 2019 May;48(4):524-536. doi: 10.1111/vsu.13187. Epub 2019 Feb 28.

PMID:
30820980
37.

An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance.

Xu S, Ware KE, Ding Y, Kim SY, Sheth MU, Rao S, Chan W, Armstrong AJ, Eward WC, Jolly MK, Somarelli JA.

J Clin Med. 2019 Feb 7;8(2). pii: E205. doi: 10.3390/jcm8020205.

38.

The promise of immunotherapy in genitourinary malignancies.

Zhang T, Armstrong AJ, George DJ, Huang J.

Precis Clin Med. 2018 Dec;1(3):97-101. doi: 10.1093/pcmedi/pby018. Epub 2018 Dec 19.

39.

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):428-437. doi: 10.1038/s41391-019-0126-5. Epub 2019 Jan 21.

PMID:
30664736
40.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
41.

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.

Armstrong AJ, Nordle O, Morris M.

JAMA Oncol. 2019 Feb 1;5(2):270-271. doi: 10.1001/jamaoncol.2018.5874. No abstract available.

PMID:
30543364
42.

An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men.

Armstrong AJS, Shaffer M, Nusbacher NM, Griesmer C, Fiorillo S, Schneider JM, Preston Neff C, Li SX, Fontenot AP, Campbell T, Palmer BE, Lozupone CA.

Microbiome. 2018 Nov 5;6(1):198. doi: 10.1186/s40168-018-0580-7.

43.

Updates in advanced prostate cancer 2018.

Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):449-450. doi: 10.1038/s41391-018-0100-7. Epub 2018 Oct 2. No abstract available.

PMID:
30279577
44.

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.

Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H.

Pharmacol Ther. 2019 Feb;194:161-184. doi: 10.1016/j.pharmthera.2018.09.007. Epub 2018 Sep 28. Review.

PMID:
30268772
45.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

46.

Precision Medicine Approaches When Prostate Cancer Akts Up.

Zhang T, George DJ, Armstrong AJ.

Clin Cancer Res. 2019 Feb 1;25(3):901-903. doi: 10.1158/1078-0432.CCR-18-2491. Epub 2018 Sep 11.

47.

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM.

Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.

48.

Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.

Wu M, Huang PH, Zhang R, Mao Z, Chen C, Kemeny G, Li P, Lee AV, Gyanchandani R, Armstrong AJ, Dao M, Suresh S, Huang TJ.

Small. 2018 Aug;14(32):e1801131. doi: 10.1002/smll.201801131. Epub 2018 Jul 3.

49.

Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.

Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.

50.

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Brown LC, Sonpavde G, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):419-430. doi: 10.1038/s41391-018-0049-6. Epub 2018 Jun 1.

PMID:
29858595

Supplemental Content

Loading ...
Support Center